Ilumya in Psoriasis Management
Psoriasis presents a chronic challenge for patients and clinicians. Effective treatment options remain crucial in improving patient outcomes. Ilumya (tildrakizumab-asmn) offers a promising therapeutic solution. It is an interleukin-23 antagonist that targets the immune pathways responsible for the skin condition. This article examines Ilumya’s role in advancing psoriasis management, comparing it with traditional treatments and …